XL-647 (BioDeep_00000798346)
代谢物信息卡片
化学式: C24H25Cl2FN4O2 (490.1338501999999)
中文名称: 特伐替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CC2CC(CC2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC
InChI: InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:167674
- KEGGdrug: D11772
- PubChem: 10458325
- DrugBank: DB11973
- ChEMBL: CHEMBL3544983
- CAS: 1000599-06-3
- CAS: 781613-23-8
分类词条
相关代谢途径
Reactome(4)
BioCyc(0)
PlantCyc(0)
代谢反应
3 个相关的代谢反应过程信息。
Reactome(3)
- Disease:
ADORA2B + Ade-Rib ⟶ ADORA2B:Ade-Rib - Diseases of signal transduction by growth factor receptors and second messengers:
H+ + Oxygen + TPNH ⟶ H2O2 + TPN - Signaling by ERBB2 in Cancer:
ERBB2 KD mutants (TKI sensitive):ERBIN:HSP90:CDC37 ⟶ ERBB2 KD mutants:TKIs:ERBIN:HSP90:CDC37
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sani H Kizilbash, Shiv K Gupta, Karen E Parrish, Janice K Laramy, Minjee Kim, Gautham Gampa, Brett L Carlson, Katrina K Bakken, Ann C Mladek, Mark A Schroeder, Paul A Decker, William F Elmquist, Jann N Sarkaria. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
Molecular cancer therapeutics.
2021 06; 20(6):1009-1018. doi:
10.1158/1535-7163.mct-20-0640. [PMID: 33785646] - Eric J Rubin, Lindsey R Baden, Salim S Abdool Karim, Stephen Morrissey. Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant.
The New England journal of medicine.
2021 Jan; 384(2):e14. doi:
10.1056/nejme2100736. [PMID: 33497556] - Millie Das, Sukhmani K Padda, Adam Frymoyer, Julian Molina, Alex Adjei, Janet L Lensing, Dale Miles, Branimir I Sikic, Heather A Wakelee. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology.
2018 09; 82(3):541-550. doi:
10.1007/s00280-018-3646-0. [PMID: 30030583] - M Catherine Pietanza, Thomas James Lynch, Primo N Lara, John Cho, Ronald H Yanagihara, Nandagopal Vrindavanam, Naveed Mahfooz Chowhan, Shirish M Gadgeel, Nathan A Pennell, Roel Funke, Ben Mitchell, Heather A Wakelee, Vincent A Miller. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2012 Jan; 7(1):219-26. doi:
10.1097/jto.0b013e31822eebf9. [PMID: 22011666]